Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen has submitted an investigational new drug application to the FDA for its targeted anticancer compound, huC242-DM4.
Subscribe to our email newsletter
HuC242-DM4, ImmunoGen’s tumor-activated prodrug (TAP) compound, is in development for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small cell lung cancers.
ImmunoGen’s TAP technology uses tumor-targeting engineered antibodies to deliver a proprietary cell-killing agent specifically to cancer cells. In the case of huC242-DM4, the CanAg-targeting antibody, huC242, is used to deliver the potent cell-killing agent, DM4, specifically to CanAg-expressing cells.
Cancers that express CanAg include colorectal, pancreatic, and other gastrointestinal cancers, as well as many non-small cell lung cancers.
Dr Mitchel Sayare, chairman and CEO of ImmunoGen, commented, “ImmunoGen is committed to the aggressive development of our own products. In November 2004, we announced our decision to take forward huC242-DM4 and our goal of initiation of patient dosing with this compound in mid-2005. We remain on track to achieve that goal.”